Does Mounjaro Come in Tablet Form?

Step 1, understanding what tirzepatide is and why there is no Mounjaro tablet yet

Tirzepatide, sold in the UK as Mounjaro, is a dual GIP and GLP-1 receptor agonist made by Eli Lilly. It activates two gut-hormone pathways at once, slowing gastric emptying and signalling fullness to the brain. Right now, it is only delivered by injection. That is not a gap in the market that has been overlooked, oral delivery of large peptide molecules is genuinely difficult. The gut breaks them down before they can be absorbed in meaningful quantities, which is why GLP-1 medicines have historically been injectable. Eli Lilly is researching an oral tirzepatide formulation, but no product has reached UK licence at the time of writing. So if you have read something suggesting Mounjaro pills are available, it is likely referring to a trial phase or a US development that has not translated into an approved UK product, and our page exploring whether Mounjaro comes in pill form covers exactly why that distinction matters. For people specifically asking whether there is a tablet form of Mounjaro, the answer is the same: not yet, and not imminently.

The Mounjaro KwikPen is designed to be as straightforward as possible, a short, fine needle, pre-filled, with a single click mechanism. Many people who were anxious about injecting tell us it is far less of an ordeal than they expected. Worth knowing before ruling it out entirely.

Step 2, what oral weight-loss tablet actually does exist in the UK

A question our prescribers hear most weeks, in one form or another, is: "Is there a tablet I can take instead?" Since June 2026, the honest answer has changed. The MHRA approved Wegovy tablets (oral semaglutide co-formulated with an absorption enhancer called SNAC) on 11 June 2026, making the UK the first country in Europe to licence an oral GLP-1 medicine specifically for weight management. You can read more about how tirzepatide differs mechanically from semaglutide if you want a deeper comparison, but the short version is that they are different molecules, not different formats of the same drug.

Wegovy tablets start at 1.5mg once daily and are titrated through 4mg and 9mg up to a 25mg maintenance dose. They need to be taken first thing in the morning on an empty stomach with a small amount of plain water, with a gap of at least 30 minutes before any food, coffee or other medicines. No refrigeration is required, which many people find genuinely convenient, particularly for travel. Clinical trial data (OASIS 4, 64 weeks) showed around 13.6% average body-weight reduction versus around 2.4% with placebo; among participants who stayed fully adherent, that figure rose to approximately 17%. The MHRA's approval notice is worth reading if you want the regulator's own summary of the evidence.

Step 3, how Mounjaro's injection results compare, and why that context matters

Mounjaro's clinical evidence remains the strongest in this class in terms of average weight loss. In the SURMOUNT-1 trial, published in the New England Journal of Medicine, participants at the 15mg dose achieved around 20–21% average body-weight reduction over 72 weeks. The SURMOUNT-5 head-to-head trial, also published in the NEJM in 2025, found tirzepatide produced greater average weight loss than semaglutide 2.4mg injection over the same period. So while the new oral option is a real and meaningful addition for people who cannot or would rather not inject, the current evidence base for tirzepatide's injection formulation is extensive and well-established.

For people exploring all aspects of Mounjaro before deciding, it is also worth knowing that the licensed eligibility criteria for the two medicines differ in some respects. A prescriber looks at the full picture (your BMI, any relevant health conditions, your preferences about administration) before recommending which treatment, if any, is appropriate. The weight-loss treatment overview on our site sets out how the different licensed options sit alongside each other.

Step 4, what this means if you are considering treatment

The practical upshot is this: if you specifically want tirzepatide in tablet form, that option does not currently exist anywhere in the world under a licensed product, and our page on what the Mounjaro tablet form would involve explains the scientific and regulatory reasons behind that in more detail. If your preference for a tablet is about avoiding injections rather than specifically needing tirzepatide, then Wegovy tablets are a licensed, clinically evidenced alternative, dispensed by our GPhC-registered pharmacy following a same-day review by a qualified prescriber. If you want to understand the differences more before committing to anything, our page covering what a Mounjaro tablet would involve and where development currently stands goes into more detail on the development landscape, and our general FAQs cover the most common follow-up questions.

One thing to be cautious about: tirzepatide is only available as an injection through the licensed UK supply chain. Any seller claiming to offer Mounjaro in tablet or capsule form is not selling a genuine, MHRA-approved product. The MHRA's Yellow Card scheme exists partly to receive reports of suspect sellers, and it is worth using if you encounter them. Our clinical support team is available seven days a week if you have questions about what you have seen or been offered.

If you are ready to explore which treatment suits you, speak to our prescribers, the consultation is free, and a named clinician reviews your answers the same day.